Recombinant Cynomolgus B7-H6 Fc Chimera Protein, CF

• Reactivity: Pm-Cm
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus B7-H6 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to induce IFN-gamma secretion by NK‑92 human natural killer lymphoma cells. Brandt, C.S. et al. (2009) J. Exp. Med. 206:1495. The ED₅₀ for this effect is 0.5-2.5 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived cynomolgus monkey B7-H6 protein
  

  Cynomolgus B7-H6 (Asp25-Ser262) Accession # XP_005578557	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: XP_005578557
• N-terminal Sequence: Asp25
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: NCR3LG1
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 53 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 70-81 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus B7-H6 Fc Chimera Protein, CF

• B7 homolog 6
• B7H6
• B7-H6
• DKFZp686I21167
• DKFZp686O24166
• NCR3LG1

Background

B7-H6 is a 55 kDa glycosylated member of the B7 family of immune costimulatory proteins (1, 2). Mature B7-H6 consists of an extracellular domain (ECD) that with one Ig-like V domain and one Ig-like C1 domain, a transmembrane segment, and a cytoplasmic domain that contains one ITIM, one SH2, and one SH3 motif (3). Both of the Ig-like domains carry N-linked glycosylation (4). Within the ECD, cynomolgous B7-H6 shares 81%, 81%, 77% and 80% amino acid sequence identity with chimpanzee, orangutan, gibbon, and human B7-H6, respectively. Orthologs in mouse and rat have not been identified. The Ig-like V domain mediates 1:1 stoichiometric binding of B7-H6 to NKp30 expressed on NK cells (4, 5). It does not show binding to NKp44, NKp46, or NKG2D (3, 6). Ligation of NKp30 by B7-H6 induces NK cell activation and target cell cytolysis (3). B7-H6 is expressed on a wide range of hematopoietic, carcinoma, and melanoma tumor cells, which is consistent with the detection of NKp30 binding sites on many tumors (3, 7). B7-H6 is up-regulated on inflammatory monocytes and neutrophils, and a 30 kDa soluble fragment can be released by ADAM-10 or ADAM-17 mediated shedding (8, 9). The expression of B7-H6 on tumor cells correlates with cancer progression and patient's survival in human ovarian cancer (10).

1. Zou, W. and L. Chen (2008) Nat. Rev. Immunol. 8:467.
2. Bour-Jordan, H. et al. (2011) Immunol. Rev. 241:180.
3. Brandt, C.S. et al. (2009) J. Exp. Med. 206:1495.
4. Li, Y. et al. (2011) J. Exp. Med. 208:703.
5. Joyce, M.G. et al. (2011) Proc. Natl. Acad. Sci. USA 108:6223.
6. Arnon, T.I. et al. (2006) Semin. Cancer Biol. 16:348.
7. Byrd, A. et al. (2007) PLoS ONE 2:e1339.
8. Matta, J. et al. (2013) Blood 122:394.
9. Schlecker, E. et al. (2014) Cancer Res. 74:3429.
10. Zhou, Y. et al. (2015) Int. J. Clin. Exp. Pathol. 8:9428.

Bioinformatics

• Gene Symbol: NCR3LG1
• Uniprot:
  • XP_005578557()